Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
Author:
Publisher
Elsevier BV
Subject
Urology
Reference30 articles.
1. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know;Heidenreich;Eur Urol,2013
2. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study [abstract LBA1^];Beer;J Clin Oncol,2014
3. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013
4. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone;Schrader;Eur Urol,2014
5. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone;Bianchini;Eur J Cancer,2014
Cited by 143 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Second-Line Treatment Options in Metastatic Castration-Resistant Prostate Cancer after Progression on First-Line Androgen-Receptor Targeting Therapies: A Systematic Review and Bayesian Network Analysis;Critical Reviews in Oncology/Hematology;2024-02
2. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-12-15
3. Novel signatures of prostate cancer progression and therapeutic resistance;Expert Opinion on Therapeutic Targets;2023-12-02
4. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study;European Urology Oncology;2023-11
5. IU1 and enzalutamide combination yields synergistic effects on castration‐resistant prostate cancer;The Prostate;2023-08-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3